Merrell Dow pricing
In recent speech to the Ohio State College of Pharmacy, Merrell Dow VP-Public Affairs Robert Ingram said the company is "in effect, moving toward a true one price policy," by reducing differential between contract customers, and whslrs. and retailers. He explained that the new policy "should result in minimizing the possibility of diversion." Ingram added: "We are realizing that, regardless of what the customer is called (hospital, retailer, HMO) they are in fact competing for the same patients. We should allow them to compete equitably"
You may also be interested in...
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.